TLR4 also has the potential to become a disease progression marker in patients with colon cancer or premalignant lesions [55] as well as a biomarker of the aggressive tumor phenotype in laryngeal carcinoma and breast cancer [41, 56]. This evidence concerns the gene TLR4 and breast carcinoma.